Results 21 to 30 of about 30,536 (239)

Abnormal Ferroptosis in Myelodysplastic Syndrome

Frontiers in Oncology, 2020
BackgroundFerroptosis is a form of iron-dependent non-apoptotic cell death, with characteristics of loss of the activity of the lipid repair enzyme, glutathione (GSH) peroxidase 4 (GPX4), and accumulation of lethal reactive lipid oxygen species.
Qi Lv, Haiyue Niu, Lanzhu Yue, Jiaxi Liu, Liyan Yang, Chunyan Liu, Huijuan Jiang, Shuwen Dong, Zonghong Shao, Limin Xing, Huaquan Wang   +10 more
doaj   +1 more source

Decitabine Promotes Modulation in Phenotype and Function of Monocytes and Macrophages That Drive Immune Response Regulation

Cells, 2021
Decitabine is an approved hypomethylating agent used for treating hematological malignancies. Although decitabine targets altered cells, epidrugs can trigger immunomodulatory effects, reinforcing the hypothesis of immunoregulation in treated patients. We
Fabiana Albani Zambuzi, Priscilla Mariane Cardoso-Silva, Ricardo Cardoso Castro, Caroline Fontanari, Flavio da Silva Emery, Fabiani Gai Frantz   +5 more
doaj   +1 more source

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]

, 2014
BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari, AS Yang, C Festuccia, C Zeller, CA Stidley, CJ Piyathilake, D Ma, D Matei, D Shang, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DW Shen, E Gordian, E San Jose-Eneriz, EA Braga, F Crea, F Fang, H Iwata, H Kantarjian, H Kroeger, HM Kantarjian, J Charlet, J Shia, JA Plumb, JP Issa, JP Issa, JS Kim, K Ghoshal, K Onda, K Ramachandran, K Tikoo, KY Tse, L Ding, L Rothem, MA Kane, ML Orta, NH Nabilsi, R Zhao, RH Finnell, S Fu, S Vijayaraghavalu, SB Baylin, SS Muerkoster, T Tanaka, TB Lee, VF Chekhun, X Chang, XJ Liang, Y Li, Y Oki, Y Zhang, ZG Liu   +55 more
core   +2 more sources

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Blood, 2019
Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance.
C. Dinardo, K. Pratz, V. Pullarkat, B. Jonas, M. Arellano, P. Becker, O. Frankfurt, M. Konopleva, A. Wei, H. Kantarjian, T. Xu, W. Hong, B. Chyla, J. Potluri, D. Pollyea, A. Letai   +15 more
semanticscholar   +1 more source

Therapeutic effect of folic acid combined with decitabine on diabetic mice [PDF]

International Journal of Ophthalmology, 2023
AIM: To evaluate the therapeutic effect of folic acid combined with decitabine on diabetic mice. METHODS: The diabetic model of db/db mice were randomly divided into model group, folic acid group, decitabine group, folic acid combined with decitabine ...
Gang Du, Yong Yan, Jun-Feng Gao, Chun-Yan Guo, Xiao Shen, Xun-Wen Lei   +5 more
doaj   +1 more source

Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia.

Clinical Cancer Research, 2022
PURPOSE Acute myeloid leukemia (AML) patients unfit for, or resistant to, intensive chemotherapy are often treated with DNA methyltransferase inhibitors (DNMTis). Novel combinations may increase efficacy.
M. Baer, A. A. Kogan, S. Bentzen, Tian Mi, R. Lapidus, V. Duong, A. Emadi, S. Niyongere, C. O'Connell, Ben Youngblood, S. Baylin, F. Rassool   +11 more
semanticscholar   +1 more source

Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study

Hematology, 2023
Objective Anthracyclines and cytarabine have comprised standard induction therapy for acute myeloid leukemia (AML) for decades. Low overall survival of AML is due to non-remission or relapse after remission.
Zhibo Guo, Dan Guo, Desheng Kong, Sicheng Bian, Leilei Lin, Shengjin Fan, Qi Li, Yanqiu Zhao, Yanmeng Jiang, Jiangrong Yan, Zheren Wang, Lili Sun, Yinghua Li   +12 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: Genomics mark epigenetic dysregulation as a primary therapeutic target [PDF]

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective B therapy.
Abate F., Agostinelli C., Amente S., Berti E., Bertolini F., Brundu F., Cerroni L., Dellino G. I., Etebari M., Facchetti F., Falini B., Fuligni F., Indio V., Laginestra M. A., Melle F., Motta G., Orecchioni S., Paulli M., Piccioni R., Pileri A., Pileri S. A., Pimpinelli N., Rabadan R., Rossi M., Sabattini E., Sapienza M. R., Tabanelli V., Talarico G., Tarantino G., Tripodo C., Truni M.   +30 more
core   +2 more sources

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine

Endocrine Oncology, 2023
Downregulation of tumor suppression genes by DNA hypermethylation has been proposed as a potential cause of neuroendocrine neoplasm (NEN) formation. In this report, we present a patient simultaneously diagnosed with acute myeloid leukemia (AML) and a ...
Syed Ehsanullah, Nikolaos A Trikalinos
doaj   +1 more source

Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells

Frontiers in Pharmacology, 2023
Background: EBV-associated lymphoma is a neoplasm with a poor prognosis, highly aggressive, and progressive rapidly. There is no standard clinical treatment protocol.
Lan Lin, Xiangqin Liu, Hui Yu, H. Deng, Kun Peng, Jiang Chen, Chunlei Zhang, Tao Jiang, Xiaoqi Liu   +8 more
semanticscholar   +1 more source